<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711837</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-304</org_study_id>
    <nct_id>NCT04711837</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults Undergoing Elective Surgery.</brief_title>
  <official_title>A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco-USA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco-USA Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blinded, propofol-controlled, Phase 3 clinical&#xD;
      study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in&#xD;
      adults undergoing elective surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of general anesthesia induction</measure>
    <time_frame>From start of drug administration to MOAA/S ≤1 (up to 5 minutes)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with successful induction who maintain the desired depth of anesthesia for general elective surgery, AND without significant cardiac and respiratory depression.</measure>
    <time_frame>15 minutes from end of drug administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with any injection-site pain on Numeric Rating Scale.</measure>
    <time_frame>From start of drug administration to MOAA/S ≤1 (up to 5 minutes)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to successful induction of general anesthesia.</measure>
    <time_frame>From start of drug administration to MOAA/S ≤1 (up to 5 minutes)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to the disappearance of eyelash reflex</measure>
    <time_frame>From start of drug administration to disappearance of eyelash reflex (up to 5 minutes)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change of BIS during the period of anesthesia post study drug administration</measure>
    <time_frame>15 minutes from end of drug administration.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Use of the top-up study drug and rescue/remediation drugs.</measure>
    <time_frame>From start of drug administration to MOAA/S ≤1 (up to 5 minutes)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">351</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>HSK3486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSK3486 for induction of general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol for induction of general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>HSK3486 for induction of general anesthesia.</description>
    <arm_group_label>HSK3486</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol for induction of general anesthesia.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects undergoing elective surgery (nonemergency, noncardiothoracic, and&#xD;
             nonintracranial surgery anticipated to last at least 1 hour ).&#xD;
&#xD;
          -  Males or females, aged ≥18 years old, with American Society of Anesthesiologists&#xD;
             Physical Status (ASA PS) I to IV.&#xD;
&#xD;
          -  Body mass index (BMI) ≥18 kg/m2.&#xD;
&#xD;
          -  For all females of childbearing potential, negative pregnancy test at screening and&#xD;
             baseline. Additionally, females of childbearing potential must agree to use birth&#xD;
             control (such as condom, intrauterine device [IUD], abstinence) from the time of&#xD;
             consent until 30 days post study drug administration.&#xD;
&#xD;
          -  Capable of understanding the procedures and methods of this study, willing to sign an&#xD;
             Informed Consent Form, and to complete this study in strict compliance with the study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to deep sedation/general anesthesia or a history of adverse reaction&#xD;
             to sedation/general anesthesia.&#xD;
&#xD;
          -  Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol;&#xD;
             subject having contraindications to propofol, opioids, and their antidotes.&#xD;
&#xD;
          -  Medical condition or evidence of increased sedation/general anesthesia risk.&#xD;
&#xD;
          -  Management risks of respiratory tract and judged by the investigator to be unsuitable&#xD;
             for inclusion in the study.&#xD;
&#xD;
          -  Any medication that has the potential to interact synergistically with propofol or&#xD;
             HSK3486, including but not limited to all sedatives and hypnotics.&#xD;
&#xD;
          -  Laboratory parameters significantly out of range at screening.&#xD;
&#xD;
          -  Female subjects with a positive pregnancy test (serum or urine) at screening or&#xD;
             baseline; lactating subjects; any subject planning to get pregnant within 1 month&#xD;
             after the study (including the male subject's partner).&#xD;
&#xD;
          -  Judged by the investigator to have any other factors that make the subject unsuitable&#xD;
             for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenfeng Miao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Haisco-USA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carole Hodge, PhD</last_name>
    <phone>8584429884</phone>
    <email>carole.hodge@haisco-usa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee (Tapia) Upton</last_name>
      <phone>602-863-6363</phone>
      <email>atapia@azresearchcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anneliese Iniguez</last_name>
      <phone>626-397-2394</phone>
      <email>ainiguez@lotuscr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix Clinical Research, LLC</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffanie Littleton</last_name>
      <phone>754-205-5000</phone>
      <email>s.littleton@phoenixclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward Fox</last_name>
      <phone>773-834-5234</phone>
      <email>efox1@bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Bergese, MD</last_name>
      <phone>631-638-1214</phone>
      <email>Sergio.Bergese@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNC Health Care System</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Van Manen</last_name>
      <phone>919-843-5415</phone>
      <email>karen_vanmanen@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Research Foundation</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Uribe, MD</last_name>
      <phone>614-293-3559</phone>
      <email>alberto.uribe@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HD Research</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daneshvari Solanki</last_name>
      <email>Skolte@lotuscr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Plano Surgical Hospital</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Greene</last_name>
      <email>edionne@lotuscr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Hernandez</last_name>
      <phone>551-999-6116</phone>
      <email>bhernandez@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Woods</last_name>
      <phone>801-261-2000</phone>
      <email>swoods@jbrutah.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Elective surgery</keyword>
  <keyword>Propofol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

